KSKavitha C. Selvan

Kavitha C. Selvan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kavitha C. Selvan has a total of 139 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cumulative lifecourse cardiovascular health and interstitial lung abnormalities

    by Kavitha C. Selvan, Elsie Bunyan, Laura A. Colangelo, Anthony J. Esposito, Gabrielle Y. Liu, Sadiya S. Khan, Kevin Grudzinski, Bradford Bemiss, Gary M. Hunninghake, Raul San Jose Estepar, et al.

    Extract There are shared antecedent risk factors [1, 2] and pathobiological mechanisms [3] between pulmonary fibrosis and cardiovascular disease, suggesting these two distinct disease entities may be linked though common biological pathways. Studies consistently demonstrate a higher prevalence of cardiovascular disease among individuals with interstitial lung disease (ILD) [4]; however, these studies largely capture cardiovascular status at a single point, after pulmonary fibrosis has developed. This cross-sectional approach limits insight into whether cardiovascular health (CVH) truly represents an upstream risk factor for the development and progression of ILD.

  • Open Access

    Proteomic Associations with Fibrosis and Mortality in Interstitial Lung Abnormalities

    by Jonathan A. Rose, Heida Bjarnadottir, Seung Hoan Choi, Valborg Gudmundsdottir, Jingzhou Zhang, Matthew R. Moll, Sharmin Sultana, Laura Fernandez-Wever, Ann-Marcia C. Tukpah, Claire Cutting, et al.

    Background: Interstitial lung abnormalities (ILA) are CT findings that can represent early-stage pulmonary fibrosis. Radiologic features such as definite fibrosis stratify mortality risk; whether blood-based biomarkers can identify high-risk subsets and predict mortality is unknown.Methods: In this longitudinal multicohort study, we used aptamer-based proteomics in four ILA cohorts (COPDGene, AGES-Reykjavik, SPIROMICS, and the Framingham Heart Study) and one idiopathic pulmonary fibrosis (IPF) cohort. Associations were discovered in COPDGene, replicated in meta-analysis of the other ILA cohorts, and separately the IPF cohort. Logistic regression and Cox models identified protein associations with ILA, fibrotic ILA, and mortality; proteins were combined with demographic variables into a multiprotein model to identify fibrosis and predict mortality.Findings: 13,070 participants were included (1198 with ILA, 267 with fibrotic ILA, 100 with IPF). 231 proteins were associated with ILA in COPDGene, of which eight were associated with fibrotic ILA. In the replication cohorts, 200 proteins replicated with ILA, seven with fibrosis, and six with IPF. An eight-protein model improved discrimination of fibrosis (COPDGene area under the curve [AUC]=0·94; replication AUC=0·79; IPF AUC=0·95) and predicted mortality among those with ILA (COPDGene hazard ratio [HR]=2·5, p<0·001; replication HR=1·9, p<0·001), including when stratified by definite radiologic fibrosis.Interpretation: Peripheral blood proteins are associated with ILA, fibrotic ILA, and mortality. An eight-protein model differentiates radiologic fibrosis and predicts mortality, even in those without definite radiologic evidence of fibrosis, supporting the use of blood-based biomarkers to improve risk stratification of these common radiologic findings.Funding: US National Institutes of Health.

  • Open Access

    Treatment trajectories by radiologic pattern of lung injury in interstitial lung disease with myositis-associated antibodies: a retrospective cohort study

    by Kevin Grudzinski, Thomas C Bolig, Malek Shawabkeh, Kavitha C Selvan, Raymond J Goodwin, Emily Olson, Bradford C Bemiss, Nishant Parekh, Hatice Savas, Jane E Dematte, et al.

    Objectives: Lung involvement in interstitial lung disease (ILD) with myositis-associated antibodies (myositis-ILD) predominantly has two radiologic patterns—nonspecific interstitial pneumonia (NSIP) and organizing pneumonia (OP)—that often coexist, yet clinical outcomes of these patterns remain unclear. We aimed to describe functional and radiologic trajectories during immunomodulatory therapy by predominant radiologic pattern in myositis-ILD. Methods: In this retrospective, single-centre cohort study, we studied participants from the Northwestern University ILD Registry with a circulating myositis-associated antibody, ILD, and at least 6 months of immunomodulatory therapy during a 24-month observation period. Two thoracic radiologists assigned the predominant radiologic pattern (NSIP or OP). The primary outcome was the change in forced vital capacity (FVC); secondary outcomes were the change in diffusing capacity of the lungs for carbon monoxide (DLCO) and qualitative and quantitative (Kazerooni score) radiologic change. Groups were compared with Fisher exact and Wilcoxon rank-sum tests. Results: Forty-one participants were characterized (29 [71%] OP-predominant, 12 [29%] NSIP-predominant). Both subgroups had improved FVC on immunomodulatory therapy (OP +0.36 l [P = 0.006]; NSIP +0.25 l [P = 0.09]). DLCO did not change significantly in either subgroup (OP +1.22 [P = 0.11]; NSIP -0.75 [P = 0.37]). The OP cohort improved on qualitative imaging analysis (P < 0.05), driven by reduced groundglass/consolidative opacity (P = 0.006). Participants with NSIP/OP overlap had greater baseline radiologic severity. Conclusions: In myositis-ILD, both radiologic subgroups showed measurable functional and radiologic change during immunomodulatory therapy, with larger improvements in the OP-predominant subgroup; the magnitude of change did not differ significantly between subgroups. These descriptive, hypothesis-generating findings require multicentre validation.

  • Open Access

    Proteomic Biomarkers of Lung Injury on Chest Computed Tomography and Future Quantitative Interstitial Abnormalities and Emphysema

    by Kavitha Selvan, Raul San Jose Estepar, Yueming Liu, Anthony J. Esposito, Gabrielle Liu, Jonathan A. Rose, Laura Colangelo, Sadiya S. Khan, Bharat Thyagarajan, Nicholas Banovich, et al.

    Background: The transition from lung injury to chronic lung disease is poorly defined. We previously described a quantitative measure of visually normal lung with high attenuation (CT lung injury) associated with greater risk of progression to divergent radiologic phenotypes, including interstitial lung abnormalities and emphysema. The underlying biology of this finding remains unclear.Methods: Plasma proteomics were measured in COPDGene (phase 2) using the SomaScan platform and burden of CT lung injury was quantified. Associations between proteins and CT lung injury were evaluated using multivariable linear regression. Findings were replicated in CARDIA (year 25). In CARDIA, associations between proteins measured at year 15 and CT lung injury at year 25 were also evaluated. Proteins associated with CT lung injury in COPDGene and CARDIA years 15 and 25 were then evaluated for associations with future quantitative interstitial abnormalities (QIAs) and emphysema at year 35. Findings: Among 3,188 COPDGene participants, 252 proteins were associated with CT lung injury (FDR p<0.05). Of those, 18 had overlapping significance in CARDIA at years 15 and 25, and tissue level expression was highest in lung tissue. Ten proteins were associated with future development of QIA and 3 proteins were associated with future emphysema.Interpretations: We identified 18 proteomic biomarkers of CT lung injury, consistent across two independent cohorts of diverse age and tobacco exposure. Different proteins were associated with future development of QIAs or emphysema, raising mechanistic questions regarding biologic divergence in pathways between early lung injury and chronic lung diseases.

  • Open Access

    Clinical Utility of an FDA-Authorized Artificial Intelligence Imaging Platform in Interstitial Lung Disease Diagnosis

    by Arjun Prakash Tambe, Ryan D. Boente, Gautam George, Fayez Kheir, Omid Tahamtani Omran, Kavitha C. Selvan

    Background/Objectives: The diagnosis of interstitial lung disease (ILD) is challenging and frequently delayed. Clinically accessible and minimally invasive diagnostic tools are needed to expedite the diagnosis of ILD while minimizing risk to patients. Fibresolve is an imaging artificial intelligence (AI) tool recently approved by the Food and Drug Administration (FDA) for use in ILD diagnosis and made available to clinicians. The objective of this study was to describe its utility in clinical practice. Methods: We conducted a prospective, observational study of patients across the United States (US) in whom Fibresolve was utilized during routine clinical practice between July 2024 and June 2026. Information on patient demographics, Fibresolve test results (positive = suggestive of idiopathic pulmonary fibrosis (IPF); negative = unsupportive of IPF), and disease management pre- and post-Fibresolve utilization were collected, including the use of ILD-specific pharmacotherapy and planned and/or completed invasive diagnostic procedures. Results: There were 209 patients that underwent evaluation with Fibresolve across 47 medical centers. Of those, 16 were academic centers (n = 57 patients), and 31 were community-based (n = 152 patients). Fibresolve was positive in 89/209 (42.6%) patients. The percentage of patients receiving ILD-specific pharmacotherapy increased significantly following Fibresolve utilization (12.5% to 44.4%, p < 0.001). Pre-Fibresolve, 59/154 (38.3%) patients had an invasive diagnostic procedure planned; post-Fibresolve, only 12/77 (15.6%) patients had an invasive procedure performed (p < 0.001). Conclusions: In this real-world study evaluating the use of an FDA-authorized imaging tool for ILD diagnosis in diverse clinical practices across the US, we found that following utilization of Fibresolve, there was a statistically significant increase in the percentage of patients receiving guideline-directed therapy for ILD, and previously-planned invasive diagnostic procedures were avoided in many cases. These findings support the use of Fibresolve as an adjunct for ILD diagnosis in clinical practice.

  • Open Access

    Adult Life Course Trajectories of Lung Function and the Development of Interstitial Lung Abnormalities: The CARDIA Lung Study

    by Kevin M. Grudzinski, Gabrielle Y. Liu, Laura A. Colangelo, Kavitha C. Selvan, Rachel Putman, Gary M. Hunninghake, Raul San Jose Estepar, George Washko, Ravi Kalhan, Anthony J. Esposito

    Background: Interstitial lung abnormalities (ILA) are radiologic findings of increased lung density or fibrosis in individuals without clinical interstitial lung disease (ILD) and are associated with increased mortality and progression to ILD. Understanding physiologic trajectories of lung function preceding ILA diagnosis may illuminate early mechanisms of lung injury. Methods: We recruited participants from the Coronary Artery Risk Development in Young Adults (CARDIA) Lung Study, a prospective cohort of adults enrolled at ages 18–30 years and followed longitudinally for 25 years. Percent predicted forced vital capacity (ppFVC) was measured at five study visits over 20 years. Individual ppFVC trajectories were estimated using random coefficient models. Person-specific slopes were incorporated into logistic regression models to examine associations with visually detected ILA on chest CT at exam year 25. Models were adjusted for age, sex, race, body mass index, pack-years of smoking, and study center. Results: Among 3,136 participants with complete data, 57 (1.8%) had ILA at mean age 51 years. In univariable and multivariable models, individuals with ILA had greater cumulative decline in ppFVC over the 20 years preceding diagnosis. Each 10% absolute decline in ppFVC was associated with more than twice the odds of ILA (adjusted OR 2.21, 95% confidence interval 1.47–3.31, p = 0.0001). Conclusions: Greater longitudinal decline in FVC from early adulthood was strongly associated with the presence of ILA at midlife. These findings suggest that physiologic impairments precede radiologic evidence of subclinical parenchymal lung abnormalities, underscoring the potential of life course lung function trajectories to identify individuals at risk for developing ILD.

  • Open Access

    Therapeutic Response by Radiologic Pattern of Lung Injury in Myositis-Associated Interstitial Lung Disease: A Retrospective Cohort Study

    by Thomas C. Bolig, Kevin Grudzinski, Malek Shawabkeh, Kavitha C. Selvan, Raymond J. Goodwin, Emily Olson, Bradford C. Bemiss, Nishant Parekh, Hatice Savas, Jane E. Dematte, et al.

    Objective: Myositis-associated interstitial lung disease (myositis-ILD) consists of two predominant radiologic patterns of lung injury—nonspecific interstitial pneumonia (NSIP) and organizing pneumonia (OP)—that oftentimes coexist. However, it remains unclear whether either is associated with clinical outcomes. We aimed to assess the therapeutic response in patients with NSIP-compared to those with OP-predominant myositis-ILD. Methods: This retrospective, single-center cohort study recruited participants from the Northwestern University ILD Registry with a circulating myositis-associated antibody, ILD, and at least 6 months of follow-up while on immunomodulatory therapy during a 24-month observation period after diagnosis. Two thoracic radiologists determined the predominant radiologic pattern (NSIP or OP). The primary outcome was the absolute change in forced vital capacity (FVC) at 24 months post-diagnosis. Secondary outcomes included changes in the diffusing capacity of the lung for carbon monoxide (DLCO) and radiologic qualitative and quantitative measures of lung injury. Results: Forty-one participants were included in analyses. 71% had an OP-predominant while 29% had an NSIP-predominant radiologic pattern of lung injury. Both exposure cohorts had improvement in mean absolute FVC (OP cohort = +0.18L [p=0.005], NSIP cohort = +0.24L [p=0.07]) over the 24-month observation period. The OP (pRadiologic phenotyping may predict therapeutic response in myositis-ILD . This study demonstrates that an OP-predominant computed tomography (CT) pattern of lung injury is associated with greater improvement in lung function and radiologic signs of inflammation over 24 months on at least 6 months of immunomodulatory therapy compared with an NSIP-predominant pattern, suggesting that CT pattern may provide clinically meaningful prognostic information. First study to integrate blinded qualitative radiologic adjudication with quantitative CT scoring in myositis-ILD . By combining dual-radiologist review with Kazerooni quantitative scoring and longitudinal pulmonary function testing, this study offers a rigorous and multidimensional assessment of treatment response. Expands risk stratification beyond antibody-based toward imaging-based phenotyping strategies . In a heterogeneous population defined by diverse myositis-associated antibodies, this work introduces radiologic pattern as a practical and accessible framework for anticipating treatment responsiveness. Provides hypothesis-generating data for precision management in myositis-ILD . The findings support the concept that imaging-defined subgroups may exhibit differential therapeutic trajectories, laying groundwork for future multicenter studies integrating CT phenotype, antibody profile, and treatment strategy.


  • Open Access

    From ideal respiratory health to chronic lung disease: indicators of impaired respiratory health

    by Kavitha C. Selvan, Joseph I. Bailey, Ravi Kalhan

    1. In the past decade, the concept of ideal health has evolved [1–3]. Health was previously defined as the absence of clinically apparent disease, but this narrow view neglects to recognize importa...

  • Imaging-Based Mortality Prediction in Patients with Systemic Sclerosis

    by Alec K. Peltekian, Karolina Senkow, Gorkem Durak, Kevin M. Grudzinski, Bradford C. Bemiss, Jane E. Dematte, Carrie Richardson, Nikolay S. Markov, Mary Carns, Kathleen Aren, et al.


  • Active Antigen-Specific Adaptive Immune Responses Are Shared among Patients with Progressive Fibrotic Interstitial Lung Disease

    by Tania E. Velez, Young Me Yoon, Vaibhav Upadhyay, Sara E. Vazquez, Cathryn T. Lee, Kavitha C. Selvan, Christopher S. Law, Kelly M. Blaine, Maile K. Hollinger, Donna M. Decker, et al.

    Rationale: Enlargement of lung-associated lymph nodes (LNs) predicts worse survival in all patients with interstitial lung disease (ILD). This phenomenon occurs in both connective tissue disease–associated ILD and, surprisingly, idiopathic pulmonary fibrosis (IPF), where immune-driven pathogenesis is controversial. Objectives: To determine whether immune responses in the lung LNs of patients with ILD are antigen-specific and significant to pathology and etiology. Methods: ILD lung LNs excised at transplant (30 IPF, 7 interstitial pneumonia with autoimmune features, 4 hypersensitivity pneumonitis, 5 connective tissue disease–associated ILD, 5 other ILD) and 36 donor control lung LNs were analyzed by spectral flow cytometry. Formalin-fixed lung LNs and OCT-fixed lung samples of patients with IPF were used to determine germinal center (GC) and antigen-specific responses. Serum autoantibody responses were measured by radioligand binding assay. Measurements and Main Results: All patients with ILD revealed a common adaptive immune landscape of antigen responses in lung LNs characterized by the presence of GC B cells, T follicular helper cells, and activated T cells. Immunological synapses identified in the lung LNs demonstrated that antigen stimulation is ongoing in patients with ILD. Lung LN frequencies of T follicular helper and T regulatory cells correlated with circulating antibody concentrations to ABLIM1, a recently identified autoantigen expressed widely, including in aberrant basaloid cells that are uniquely found in fibrotic lungs. Conclusions: Antigen-induced activation and development of GC in enlarged lung LNs represents a shared immunopathologic mechanism associated with progressive pulmonary fibrosis among patients with ILD, regardless of etiology. Autoantigens overexpressed in progressive pulmonary fibrosis may be key drivers of these GC responses.